Concepedia
Statistics
Publications
8
Citations
347
H-Index
Active since
2005
Affiliations
Novartis (Switzerland)(Current)
Brigham Young University
Novartis (United States)
Novartis Institutes for BioMedical Research
Novartis (China)
Karl Miranda is an author at Novartis (Switzerland) specializing in pharmacology, drug discovery, and medicinal chemistry.
Publications per year
2005–2018
A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase
Lauren G. Monovich, Richard B. Vega, Erik L. Meredith et al. · FEBS Letters · 2009 · 58 citations
Life Sciences, Cardiology, Molecular Biology +12
Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors
Erik L. Meredith, Ophelia Ardayfio, Kimberly Beattie et al. · Journal of Medicinal Chemistry · 2010 · 54 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +16
Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors
Erik L. Meredith, Gary M. Ksander, Lauren G. Monovich et al. · ACS Medicinal Chemistry Letters · 2013 · 48 citations · Full text
Synthesis and Biological Evaluation of 6-(Alkyn-1-yl)furo[2,3<i>-d</i>]pyrimidin-2(3<i>H</i>)-one Base and Nucleoside Derivatives
Morris J. Robins, Karl Miranda, Vivek K. Rajwanshi et al. · Journal of Medicinal Chemistry · 2005 · 46 citations
Pharmacy, Chemistry, Medicinal Chemistry +15
Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D
Erik L. Meredith, Kimberly Beattie, Robin Burgis et al. · Journal of Medicinal Chemistry · 2010 · 41 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +12
1–5 of 8